BeyondSpring Q2 2025: Promising Clinical Results and Strategic Moves

BeyondSpring reported Q2 2025 earnings, highlighting clinical advancements and strategic moves. The company's lead asset Plinabulin showed promising results in a Phase 2 study for NSCLC patients, and the FDA cleared SEED Therapeutics' ST-01156. BeyondSpring reported a net loss of $1.9 million, improved from the previous year, and increased cash reserves to $9.5 million. The company aims to continue its momentum in clinical developments and strategic partnerships.

BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company, reported its second-quarter (Q2) 2025 financial results, alongside significant clinical and corporate milestones. The company highlighted promising results from its lead asset, Plinabulin, and the FDA clearance for SEED Therapeutics' ST-01156.

Plinabulin, a first-in-class agent, showed encouraging efficacy and safety data in a Phase 2 study evaluating its use in combination with pembrolizumab and docetaxel for metastatic non-small cell lung cancer (NSCLC) patients who progressed on prior PD-1/L1 inhibitors. The combination demonstrated a median progression-free survival (PFS) of 6.8 months, an objective response rate (ORR) of 18.2%, and a disease control rate (DCR) of 77%.

The FDA cleared SEED Therapeutics' Investigational New Drug (IND) application for ST-01156, a brain penetrant, novel orally administered molecular glue degrader targeting RBM39. This clearance supports the advancement of ST-01156 towards Phase 1 trials, targeting aggressive cancers including Ewing Sarcoma and KRAS-driven tumors.

BeyondSpring reported a net loss of $1.9 million for the quarter ended June 30, 2025, compared to $2.7 million for the same period in 2024. This improvement was driven by a decrease in general and administrative expenses. The company's cash and cash equivalents increased to $9.5 million as of June 30, 2025, compared to $2.9 million as of December 2024.

The company also appointed Dr. Bill Desmarais as its CFO and Chief Business Officer, bringing over two decades of leadership experience in finance, business development, and strategic expertise in biopharma and biotech.

BeyondSpring aims to continue its momentum in clinical developments and strategic partnerships, with a focus on Plinabulin and SEED Therapeutics' targeted protein degradation therapies. The company's financial results and corporate updates underscore its commitment to transforming cancer treatment and addressing high unmet medical needs.

References:
[1] https://finance.yahoo.com/news/beyondspring-reports-second-quarter-2025-120000682.html
[2] https://www.globenewswire.com/news-release/2025/08/13/3132541/0/en/BeyondSpring-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update-Accelerates-Momentum-with-Promising-Clinical-Advances-and-Strategic-Leadership-Appointment.html